造血干细胞基因治疗Wiskott-Aldrich综合征的结局
报告5例重型Wiskott-Aldrich综合征患者接受慢病毒载体基因治疗的1/2期临床试验结果,中位随访7.6年,全部存活且多系基因标记持续存在,湿疹、感染和出血素质普遍改善,免疫功能持续改善;2例有自身免疫史者出现自身免疫复发,与调节性B细胞和调节性T细胞恢复不良相关。
要点
- 5例重型WAS患者接受慢病毒载体基因治疗,中位随访7.6年全部存活且多系基因标记持续存在。
- 湿疹、感染和出血素质普遍临床改善,免疫功能持续改善。
- 2例有自身免疫史者基因治疗后自身免疫复发,伴Treg、Breg和过渡型B细胞数值恢复不良。
核心结论
- 基因治疗可改善WAS的临床和实验室表现,安全性可接受。
研究设计与样本
- 1/2期临床试验,纳入5例重型WAS患者,采用自灭活慢病毒载体表达人WAS互补DNA,由1.6-kB自体内源启动子片段调控,经白消安和氟达拉滨预处理后转导自体CD34+细胞。
主要发现
- 全部患者存活且健康,多系载体基因标记持续存在,中位随访7.6年。
- 湿疹、感染和出血素质普遍临床改善,免疫功能持续改善,尽管转基因WAS蛋白表达水平低于生理水平。
- 血小板计数和髓系细胞骨架功能改善在转导产物中载体拷贝数高的患者中最明显。
- 2例有自身免疫史的患者基因治疗后出现自身免疫复发,其WAS蛋白表达细胞百分比和基因标记与无自身免疫者相似。
- 自身免疫复发患者表现为T细胞和调节性T细胞(Treg)、产生白细胞介素-10的调节性B细胞(Breg)及过渡型B细胞的数值恢复不良。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by combined immunodeficiency, eczema, microthrombocytopenia, autoimmunity, and lymphoid malignancies. Gene therapy (GT) to modify autologous CD34+ cells is an emerging alternative treatment with advantages over standard allogeneic hematopoietic stem cell transplantation for patients who lack well-matched donors, avoiding graft-versus-host-disease. We report the outcomes of a phase 1/2 clinical trial in which 5 patients with severe WAS underwent GT using a self-inactivating lentiviral vector expressing the human WAS complementary DNA under the control of a 1.6-kB fragment of the autologous promoter after busulfan and fludarabine conditioning. All patients were alive and well with sustained multilineage vector gene marking (median follow-up: 7.6 years). Clinical improvement of eczema, infections, and bleeding diathesis was universal. Immune function was consistently improved despite subphysiologic levels of transgenic WAS protein expression. Improvements in platelet count and cytoskeletal function in myeloid cells were most prominent in patients with high vector copy number in the transduced product. Two patients with a history of autoimmunity had flares of autoimmunity after GT, despite similar percentages of WAS protein-expressing cells and gene marking to those without autoimmunity. Patients with flares of autoimmunity demonstrated poor numerical recovery of T cells and regulatory T cells (Tregs), interleukin-10-producing regulatory B cells (Bregs), and transitional B cells. Thus, recovery of the Breg compartment, along with Tregs appears to be protective against development of autoimmunity after GT. These results indicate that clinical and laboratory manifestations of WAS are improved with GT with an acceptable safety profile. This trial is registered at clinicaltrials.gov as #NCT01410825.
引用
- Labrosse R, Chu JI, Armant MA, et al. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023. PMID: 37478401. doi:10.1182/blood.2022019117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。